<DOC>
	<DOC>NCT01521702</DOC>
	<brief_summary>The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy). This study will be performed in compliance with the study protocol, GCP (good clinical practice) and the applicable regulatory requirements.</brief_summary>
	<brief_title>NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>resectable adenocarcinoma of the pancreatic head (requiring duodenopancreatectomy) T13, Nx, M0 (UICC 6th version, 2002) infiltration of the portal vein (&lt;180°) is not an exclusion criterion cytologic or histologic confirmation of adenocarcinoma age &gt;18 years written informed consent contraindication for Whipple procedure an infiltration &gt;180° of the portal vein abutment of the tumor to the superior mesenteric artery infiltration of the superior mesenteric artery or the celiac trunk chronic neuropathy &gt; grade 2 WHO performance score &gt;2 uncorrectable cholestasis (bilirubin &gt; 100mmol/l despite drainage attempts for more than four weeks prior to inclusion) female patients in child bearing age not using adequate contraception (oral or subcutaneous contraceptives, intrauterine pessars (IUP), condoms) pregnant or lactating women mental or organic disorders which could interfere with giving informed consent or receiving treatments Second malignancy diagnosed within the past 5 years, except nonmelanomatous skin cancer or noninvasive cervical cancer percutaneous biopsy of the primary tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>pancreatic head</keyword>
</DOC>